Alecardio

Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent Acute Coronary Syndrome event and type 2 diabetes mellitus (T2D)

Alecardio [NCT01042769]

Description: Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent Acute Coronary Syndrome event and type 2 diabetes mellitus (T2D)

Drug: Aleglitazar; Drug: Placebo

Primary Investigator: Kereiakes

Drug/Device Information
Aleglitazar (potent dual PPAR agonist) vs placebo (Add on therapy)
At least 2.5 year cardiovascular event trial
Roche
Major Inclusion and Exclusion
Must be randomized within 2-6 weeks post ACS/MI event
Must be Type II DM (can be new diagnosis)
Can not currently be on a TZD and/or fibrate